Floatz Rating
B57/100
Confidence
Indicative
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06121180CT.gov Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | — | Recruiting | — | — | — |
NCT03712904CT.gov Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma | — | Terminated | — | — | — |
NCT00450255CT.gov VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Uveal Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ziv-Aflibercept (this asset) | H. Lee Moffitt Cancer Center and Research Institute | P2 | B · 57 |
| Ifa | Craig L Slingluff, Jr | P2 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2/3 | BB |
| Sargramostim | Thomas Jefferson University | P3 | BB |
| Gm-Csf | Ahmad Tarhini | P2 | BB |
| Darovasertib | IDEAYA Biosciences | P3 | BB |
| Thalidomide | Memorial Sloan Kettering Cancer Center | P2 | BB |
| Pembrolizumab | BioInvent International AB | P2/3 | BB |
+42 more in the Uveal Melanoma cohort
Other indications for Ziv-Aflibercept
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | BB · 69 |
| Melanoma | — | P2 | BB · 66 |
| Cutaneous Melanoma | — | P2 | B · 63 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ziv-Aflibercept in Uveal Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ziv-aflibercept-uveal-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →